Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.44 |
| ▸ | HTR2B | P41595 | 6/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 8/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19709293 | 0.88 | ADAMTS5 (0.47) | HTR2CHTR2BADAMTS5HTR2ASLC6A2 | |
| SCHEMBL5630128 | 0.84 | RAD52 (0.46) | HTR2CHTR2BRAD52MMP2ADAMTS5 | |
| SCHEMBL5633042 | 0.84 | RAD52 (0.46) | HTR2CHTR2BRAD52MMP2ADAMTS5 | |
| SCHEMBL30609666 | 0.84 | RAD52 (0.46) | HTR2CHTR2BRAD52MMP2ADAMTS5 | |
| SCHEMBL5630986 | 0.84 | RAD52 (0.46) | HTR2CHTR2BRAD52MMP2ADAMTS5 | |
| SCHEMBL17884975 | 0.83 | RAD52 (0.50) | HTR2CHTR2BRAD52MMP14ADAMTS5 | |
| Hydrochloric Acid SCHEMBL5631472 | 0.82 | RAD52 (0.48) | HTR2CHTR2BRAD52MMP2ADAMTS5 | |
| Hydrochloric Acid SCHEMBL5631467 | 0.82 | RAD52 (0.48) | HTR2CHTR2BRAD52MMP2ADAMTS5 | |
| Hydrochloric Acid SCHEMBL5632859 | 0.82 | RAD52 (0.48) | HTR2CHTR2BRAD52MMP2ADAMTS5 | |
| SCHEMBL5631834 | 0.82 | RAD52 (0.43) | HTR2CHTR2BRAD52MMP2MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-10-07 | — | — | US | disclosed |
| US-10941117-B2 | 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2021-03-09 | — | — | US | disclosed |
| US-20200216397-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2020-07-09 | — | — | US | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| EP-3237406-B1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-02-06 | — | — | EP | disclosed |
| EP-3237406-B1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-02-06 | — | — | EP | disclosed |
| US-9926281-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2018-03-27 | — | — | US | disclosed |
| US-9926281-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2018-03-27 | — | — | US | disclosed |
| US-20180002293-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2018-01-04 | — | — | US | disclosed |
| WO-2016102347-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216397-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS1, ADAMTS5, ADAMTS7 | HTR2C 2380/4885HTR2B 1760/4885RAD52 4493/4885 |
| US-20180002293-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS1, ADAMTS5, ADAMTS7 | HTR2C 2380/4885HTR2B 1760/4885RAD52 4493/4885 |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS1, ADAMTS5, ADAMTS7 | HTR2C 2380/4885HTR2B 1760/4885RAD52 4493/4885 |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | HTR2C 2380/4885HTR2B 1760/4885RAD52 4493/4885 |
| US-10941117-B2 | 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS5, ADAMTS1, ADAMTS7 | HTR2C 2439/4885HTR2B 1816/4885RAD52 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.